MedMira Increases Sales Capacity in Canada, Adding VWR as Distributor

    HALIFAX, July 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, announced today that VWR International, LLC (VWR) has joined the
Company's Canadian distribution network. Headquartered in West Chester,
Pennsylvania, VWR is a global laboratory supply and distribution company with
worldwide sales in excess of $3.7 billion.
    "Canada is an important market for MedMira and increasing our sales
capacity with new distribution channels is key to maintaining and expanding
our market position. Adding VWR to our Canadian distribution network will
boost our sales revenues and enable us to develop and capitalize on
opportunities to launch new products in Canada," said Hermes Chan, CEO,
MedMira.
    "We provide our customers with the most innovative products available on
the market today. Adding MedMira's 3-minute rapid HIV test to our product
portfolio will provide our Canadian customers with a critical diagnostic
tool," said Mark McLoughlin, Senior Vice President, Category Management North
America, VWR.

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.%SEDAR: 00013053E

For further information: Andrea Young, MedMira, [phone],
[e-mail]